Cytokine release syndrome and CAR T Cell therapy: Modulating the intensity of the inflammatory response and resolution within the tumor microenvironment
CAR T cell therapy achieves high degrees of success with respect to complete response and overall response rates in many hematological cancers, especially lymphomas. Compared to other immunotherapies, these “activated” blood products are plagued by a high incidence of a severe systemic inflammatory...
Saved in:
| Main Authors: | David F. Driscoll, Bruce R. Bistrian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1615526/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion
by: Shufeng Xie, et al.
Published: (2025-03-01) -
Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights
by: Jiasi Zhang, et al.
Published: (2025-06-01) -
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report
by: Tyler Ruemmele, et al.
Published: (2025-04-01) -
Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
by: Qianyi Zhou, et al.
Published: (2025-03-01) -
A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
by: Yang J, et al.
Published: (2025-04-01)